Obermatt
See Similar Stocks →

Flags

Financial distress

MeiraGTx

NSQ:MGTX · KYG596651029
BiotechnologySmall

360

18
Profit price57
Owner Earnings Yield1
Dividend Yield1
Price/Sales65
EV / Gross Profit27
Price/Book91
Returns on capital4
EBIT Margin18
Gross Profitability71
Accruals95
Owner Earnings Margin41
Sales growth33
Profit growth47
Reinvestment74
Price momentum58
Debt load1
Refinancing5
Debt Payback1
Liquidity78
Analyst ratings57
Opinion Changes50
Price Target Upside79
Market mood71
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MeiraGTx clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2018
Websitemeiragtx.com
ISINKYG596651029
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsChronic DiseasesOphthalmologyNeurologyNeuroscienceCentral Nervous SystemGenetic DisorderOncologyTherapeutics

Description

MeiraGTx Holdings plc (‘MeiraGTx’) operates as a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated r…

Analysis

Middle-of-the-road

MeiraGTx Holdings plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
41
2026

All-time high

41

Jun 2026

All-time low

31

Mar 2026

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
65
—
—
—
Price/Earnings
52
—
—
—
Price/Book
91
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
81
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MeiraGTx with its peers
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Lexeo Therapeutics
NMQ:LXEO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sionna Therapeutics
NMQ:SION
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Design Therapeutics
NSQ:DSGN
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eupraxia Pharmaceuticals
TOR:EPRX
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Anavex Life Sciences
NSQ:AVXL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →